SCHEMBL20255231

SCHEMBL20255231

NC(=O)Nc1ccc(I)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.52
▸ PEPD P12955 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ MAPT P10636 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ KIF11 P52732 6/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ DYRK1B Q9Y463 2/20 0.40
▸ CLK1 P49759 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ DYRK2 Q92630 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.38
▸ KCNQ3 O43525 2/20 0.37
▸ KCNQ2 O43526 2/20 0.37
▸ KCNE1 P15382 1/20 0.37
▸ KCNQ1 P51787 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18291269 0.85 ALDH1A1 (0.39) ALDH1A1PEPDNPC1MAPTGAA
SCHEMBL20037755 0.81 SMN1; SMN2 (0.50) ALDH1A1NPC1MAPTMEN1LMNA
SCHEMBL9413742 0.78 ALDH1A1 (0.53) ALDH1A1PEPDNPC1MAPTGAA
SCHEMBL2446207 0.78 ALDH1A1 (0.53) ALDH1A1PEPDNPC1MAPTGAA
SCHEMBL20255457 0.78 SMN1; SMN2 (0.43) ALDH1A1NPC1MAPTGAAMEN1
SCHEMBL4007229 0.77 NPSR1 (0.54) ALDH1A1PEPDNPC1MAPTGAA
SCHEMBL16785423 0.77 KCNQ3 (0.60) ALDH1A1PEPDNPC1KCNQ3KCNQ2
SCHEMBL14329107 0.77 L3MBTL1 (0.60) ALDH1A1NPC1MAPTLMNA
SCHEMBL20037623 0.75 SMN1; SMN2 (0.48) NPC1MAPTGAAMEN1LMNA
Hydrochloric Acid SCHEMBL21645396 0.74 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 ALDH1A1 944/4885PEPD 1085/4885NPC1 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback